Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2023-04-18 00:00:00 ET · period of report 2023-04-17 · accession 0001209191-23-024722 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-04-18 | 2023-04-17 | VKTX | ZANTE GREG | CFO | S - Sale+OE | $20.00 | -7,500 | 149.3K | -5% | -$150.0K |
| D | 2023-04-18 | 2023-04-17 | VKTX | ZANTE GREG | CFO | M - OptEx | $13.07 | +7,500 | 156.8K | +5% | +$98.0K |
| D | 2023-04-18 | 2023-04-17 | VKTX | ZANTE GREG | CFO | M - OptEx | $0.00 | -7,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2023-04-17 | S | D | 7,500 | $20.00 | 149,279 | D | — | — | |
| 2 | Common | Common Stock, par value $0.00001 per share | 2023-04-17 | M | A | 7,500 | $13.07 | 156,779 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-04-17 | M | D | 7,500 | $0.00 | 0 | D | $13.07 · 2018-08-31 to 2028-08-31 | 7,500 Common Stock | (F2) One-third of the shares subject to the option vested on the grant date and one-third of the shares subject to the option vested on each one year anniversary of the grant date of August 31, 2018. |